Prakt. lékáren. 2007; 3(2): 62-66

Farmakoterapie ischemické choroby srdeční

doc. MUDr. Radomír Hrdina CSc
Univerzita Karlova v Praze, Farmaceutická fakulta, Hradec Králové

Ischemická choroba srdeční (ICHS) je nejčastější příčinou smrti ve vyspělých zemích. Téměř vždy vzniká jako důsledek aterosklerózy koronárních tepen. Tento článek je zaměřen na popis, léčbu a prevenci dvou nejčastějších forem ICHS – anginy pectoris a akutního infarktu myokardu. V terapii se užívá několik základních skupin léčiv – nitráty, betablokátory, blokátory vápníkových kanálů, antiagregancia, antikoagulancia a trombolytika. Zmíněné skupiny léčiv jsou charakterizovány obecně z hlediska mechanizmu účinku, jsou uvedeni jejich jednotliví zástupci registrovaní v ČR včetně firemních názvů a jejich dávkování.

Keywords: ischemická choroba srdeční, angina pectoris, akutní infarkt myokardu, nitráty, β-blokátory, blokátory vápníkových kanálů, antiagregancia, antikoagulancia, trombolytika

Published: May 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrdina R. Farmakoterapie ischemické choroby srdeční. Praktické lékárenství. 2007;3(2):62-66.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beers MH, Berkow R. The Merck manual of diagnosis and therapy. Chapter 202: Coronary artery disease. 17th ed. Whitehouse Station: Merck research laboratories 1999: 1658-1681.
    2. Cannon ChE, Smith SC. Unstable coronary syndromes. Posthospital management of acute myocardial infarction. In: Crawford MH, DiMarco JP et al. Cardiology. London:Mosby 2001: 2: 18. 1-2: 18. 12.
    3. Fiore LD et al. Department of veterans affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study. Circulation 2002; 105: 557-563. Go to original source... Go to PubMed...
    4. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685. Go to original source...
    5. Gruppo per lo Studio della Sopravvivenza nell' infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
    6. Hurlen M et al. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002; 347: 969-974. Go to original source... Go to PubMed...
    7. Kolektiv. Medical Tribune Brevíř. 15. vydání. Praha: Medical Tribune CZ 2006. 1184 s.
    8. Koster RW, Dunning AJ. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. N Engl J Med 1985; 313: 1105-1110. Go to original source... Go to PubMed...
    9. Libby P. Atherosclerosis. In: Fauci AS et al. Harrison´s principles of internal medicine. 14th ed, vol. 1. New York: McGraw-Hill1998: 1345-1352.
    10. Michel T. Treatment of myocardial ischemia. In. Brunton LL et al. Goodman and Gilman´s The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill 2006: 823-844.
    11. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294. Go to original source... Go to PubMed...
    12. Rang HP et al. Pharmacology. 4th ed. Edinbugh: Churchill Livingstone 2003: 173-176.
    13. Staněk V. Léčba infarktu myokardu. In: Kölbel F et al. Trendy soudobé kardiologie.Praha:Galén 1995: 74-103.
    14. Verheugt FWA. Unstable coronary syndromes. Early phase of acute myocardial infarction. In: Crawford MH, DiMarco JP et al. Cardiology. London: Mosby 2001: 2: 14. 1-2: 14. 10.
    15. Vokurka M, Hugo J a kol. Velký lékařský slovník. 4. vydání. Praha: Maxdorf 2004: 46.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.